financetom
Business
financetom
/
Business
/
Mesoblast to File Biologics License Application for Ryoncil
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mesoblast to File Biologics License Application for Ryoncil
Jul 1, 2024 1:19 AM

03:48 AM EDT, 07/01/2024 (MT Newswires) -- Mesoblast (MESO) said Monday it would file a biologics license application with the US Food and Drug Administration next week for approval of Ryoncil, or remestemcel-L, to treat children with steroid-refractory acute graft versus host disease.

Price: 6.66, Change: -0.15, Percent Change: -2.20

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved